Application
Western blot analysis of extracts from Hela cells untreated or treated with EGF using eIF4B (phospho-Ser422) AntibodyApplication
Immunohistochemical analysis of paraffin-embedded human lung carcinomatissue using eIF4B (Phospho-Ser422) Antibody (left) or the same antibody preincubated with blocking peptide (right).Application
Western blot analysis of extracts from Hela cells untreated or treated with EGF using eIF4B (phospho-Ser422) Antibody .| Product Name | eIF4B (phospho Ser422) antibody |
|---|---|
| Antibody Type | Primary Antibodies |
| Product description | Rabbit Polyclonal antibody to eIF4B (Phospho Ser422)Required for the binding of mRNA to ribosomes. Functions in close association with EIF4-F and EIF4-A. Binds near the 5'-terminal cap of mRNA in presence of EIF-4F and ATP. Promotes the ATPase activity and the ATP-dependent RNA unwinding activity of both EIF4-A and EIF4-F. |
| Immunogen | Peptide sequence around phosphorylation site of Serine 422 (T-G-S(p)-E-S) derived from Human eIF4B. |
| Modification | p-Ser422 |
| Clonality | Polyclonal |
|---|---|
| Host Species | Rabbit |
| Tested Applications | IHC-PWB |
| Suggested starting dilutions are as follows. WB: 1:500~1:1000, IHC-P: 1:50~1:100. Not yet tested in other applications. Optimal working dilutions should be determined experimentally by the end user.: |
|
| Species Reactivity | HumanMouse |
| Concentration | 1mg/ml (Please refer to the vial label for the specific concentration) |
| Purification | Affinity purified |
| Gene Synonyms | EIF-4B PRO1843 EIF4B eukaryotic translation initiation factor 4B |
|---|---|
| Target | eIF4B (Phospho Ser422) |
| Molecular Weight(MW) | 80 (note) |
Application
Western blot analysis of extracts from Hela cells untreated or treated with EGF using eIF4B (phospho-Ser422) Antibody
Application
Immunohistochemical analysis of paraffin-embedded human lung carcinomatissue using eIF4B (Phospho-Ser422) Antibody (left) or the same antibody preincubated with blocking peptide (right).
Application
Western blot analysis of extracts from Hela cells untreated or treated with EGF using eIF4B (phospho-Ser422) Antibody .| Application Notes | Suggested starting dilutions are as follows. WB: 1:500~1:1000, IHC-P: 1:50~1:100. Not yet tested in other applications. Optimal working dilutions should be determined experimentally by the end user.: |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | Keep as concentrated solution. Aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. |
